深圳市美好创亿医疗科技股份有限公司2025年度利润分配及资本公积转增股本预案公告

美好医疗（301363）：发布2025年度利润分配及资本公积转增股本预案

重点内容解读

2025年度利润分配及资本公积转增股本预案出炉：公司拟以2025年底总股本567,739,132股（已扣除回购股份）为基数，向全体股东每10股派发现金红利2.00元（含税），合计派发现金红利113,547,826.40元（含税）。
资本公积转增股本：公司还计划以资本公积向全体股东每10股转增4股，转增后公司总股本将增至795,966,832股（含回购股份1,132,048股）。
不送红股，未分配利润结转：此次方案不进行送红股，剩余未分配利润将结转至以后年度分配。
分红比例高：如果年度股东大会审议通过，2025年度现金红利将占归属于上市公司股东净利润的56.16%，显示公司注重股东回报。
预案实施前股本变动将作相应调整：如2025年内因新增股份等导致总股本变动，将按比例调整分配总额。
合规经营，分红连年持续：2023-2025年累计现金分红金额达2.64亿元，高于三年年均净利润30%的要求，符合深交所创业板分红政策，不触及风险警示。
研发投入持续增加：2025年度研发投入1.34亿元，三年累计投入3.95亿元，占累计营业收入8.66%。
财务稳健，资产结构健康：2025年期末相关金融资产占总资产5.01%，2024年为12.54%，远低于50%的警戒线。
风险提示：本预案尚需2025年年度股东大会审议通过，存在不确定性。

对股东及投资者可能影响

分红方案优厚，或利好股价：较高的现金分红比例和资本公积转增，有望提升投资者信心，对公司股价形成积极影响。
股本增厚，流动性增强：每10股转增4股有助于优化公司股本结构，提高股票流动性。
公司稳健经营且持续回报股东：连续三年高比例分红，显示公司盈利能力和现金流健康，强化市场对公司价值的认可。
存在不确定性：方案需经过年度股东大会审议，最终实施情况需关注后续进展。

详细财务数据披露

项目	2025年度	2024年度	2023年度
归属于上市公司股东的净利润（元）	283,080,971.90	363,776,477.42	313,300,575.05
现金分红总额（元）	113,547,826.40	45,419,130.56	40,552,795.20
研发投入（元）	133,823,843.76	140,575,368.64	120,403,232.88
营业收入（元）	1,625,486,540.42	1,594,208,109.70	1,337,586,673.34
累计现金分红总额（元，近三年）	264,328,560.00
累计研发投入总额（元，近三年）	394,802,445.28
累计研发投入/累计营业收入（%）	8.66

其他说明

公司已严格履行内幕信息保密和防止内幕交易义务。
本次利润分配预案及相关数据已通过标准无保留意见的审计。
备查文件包括董事会决议和2025年度审计报告。

免责声明

本文信息内容仅供参考，不构成任何投资建议。投资者请注意相关风险，关注公司后续公告及股东大会决议。

Meihao Medical (301363) Announces 2025 Profit Distribution and Capital Reserve to Share Capital Plan

Key Highlights

2025 Profit Distribution and Share Capital Increase Plan: The company plans to distribute a cash dividend of RMB 2.00 (tax included) for every 10 shares based on the total share capital of 567,739,132 shares (after deducting repurchased shares) as of the end of 2025. The total cash dividend to be distributed will be RMB 113,547,826.40 (tax included).
Capital Reserve to Share Capital: Additionally, the company proposes to convert capital reserve into share capital at a ratio of 4 new shares for every 10 shares held. After the conversion, the total share capital will increase to 795,966,832 shares (including 1,132,048 repurchased shares).
No bonus shares; undistributed profits carried forward: There will be no bonus shares distributed, and undistributed profits will be carried forward to future years.
High payout ratio: If approved by the annual shareholders’ meeting, the 2025 cash dividend will account for 56.16% of the net profit attributable to shareholders, reflecting the company’s commitment to shareholder returns.
Adjustments for share capital changes before implementation: If there are changes in share capital before the ex-dividend date (such as new shares issued, restricted stock vested, or share repurchase), the distribution amount will be adjusted accordingly.
Compliant and sustainable dividend policy: The cumulative cash dividend for 2023-2025 totals RMB 264 million, exceeding 30% of the three-year average net profit, in line with ChiNext dividend policy and not triggering any risk warnings.
Consistent R&D investment: R&D expenses for 2025 reached RMB 134 million, with a three-year cumulative total of RMB 395 million, accounting for 8.66% of total revenue.
Financially sound and healthy asset structure: Relevant financial assets accounted for 5.01% of total assets at end-2025 (12.54% at end-2024), well below the 50% risk threshold.
Risk Warning: The plan is subject to approval at the 2025 annual shareholders’ meeting and may change.

Potential Impact on Shareholders and Investors

Generous dividend plan, potential share price catalyst: The high cash dividend and capital reserve transfer are likely to boost investor confidence and positively influence the share price.
Enhanced share capital and liquidity: The 4-for-10 capital reserve conversion will optimize capital structure and improve share liquidity.
Continuous and stable shareholder returns: Sustained high dividend payouts over three years demonstrate robust profitability and cash flow, reinforcing market confidence in the company.
Uncertainty remains: Actual implementation depends on shareholder approval; investors should monitor further developments.

Detailed Financial Data

Item	2025	2024	2023
Net profit attributable to shareholders (RMB)	283,080,971.90	363,776,477.42	313,300,575.05
Total cash dividend (RMB)	113,547,826.40	45,419,130.56	40,552,795.20
R&D expenses (RMB)	133,823,843.76	140,575,368.64	120,403,232.88
Operating revenue (RMB)	1,625,486,540.42	1,594,208,109.70	1,337,586,673.34
Three-year total cash dividend (RMB)	264,328,560.00
Three-year total R&D investment (RMB)	394,802,445.28
R&D investment/total revenue (%)	8.66

Other Notes

The company has strictly controlled insider information and fulfilled its obligations to prevent insider trading.
The profit distribution plan and related figures have been audited with an unqualified opinion.
Reference documents include the Board resolution and the 2025 annual audit report.

Disclaimer

The above information is for reference only and does not constitute investment advice. Investors should pay attention to related risks and follow further company announcements and shareholder meeting resolutions.

深圳市美好创亿医疗科技股份有限公司2025年度利润分配及资本公积转增股本预案公告

美好医疗（301363）：发布2025年度利润分配及资本公积转增股本预案

重点内容解读

对股东及投资者可能影响

详细财务数据披露

其他说明

免责声明

Meihao Medical (301363) Announces 2025 Profit Distribution and Capital Reserve to Share Capital Plan

Key Highlights

Potential Impact on Shareholders and Investors

Detailed Financial Data

Other Notes

Disclaimer

View 美好医疗 Historical chart here

Related Posts

广州岭南控股2025年度利润分配预案公告：每10股派0.51元现金红利，分红总额超3400万元

华峰化学股东完成股份减持计划，累计减持3619万股占总股本0.73%

漱玉平民大药房为控股子公司福建恒生提供担保进展公告（2026年3月）

Join Our Investing Seminar